{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:04:37Z","timestamp":1758672277675,"version":"3.44.0"},"reference-count":21,"publisher":"Baishideng Publishing Group Inc.","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Clin Oncol"],"abstract":"<jats:p>BACKGROUND<\/jats:p>\n          <jats:p>Aberrant microRNAs expression and associated pathways have been proved participate in regulation vast various physiologic and pathologic processed of different human cancers including liver cancer. While, the function of miR-451a in liver cancer still indistinct.<\/jats:p>\n          <jats:p>AIM<\/jats:p>\n          <jats:p>To study the effect of miR-451a in liver cancer development.<\/jats:p>\n          <jats:p>METHODS<\/jats:p>\n          <jats:p>GeneChip microarray analysis performed to detect miR-451a expression in liver cancer tissues and normal liver tissues. Reverse transcription-polymerase chain reaction was used to validate the expression of miR-451a in liver cancer cell and other tumor cell lines. Construction of liver cancer cell lines that stably overexpressed miR-451a by transfecting Lentivirus produced by Genechem company. Methylthiazolyldiphenyl-tetrazolium (MTT) bromide assay and colony formation assay to determine the effect of miR-451a in liver cancer cell proliferation. Flow cytometry used to investigate whether miR-451a involved in liver cancer cell apoptosis. Cell migration ability was measured via  wound scratch assay. Target gene was explored by bioinformatic analysis, and downstream molecule of miR-451a in liver cancer identified by rescue experiments.<\/jats:p>\n          <jats:p>RESULTS<\/jats:p>\n          <jats:p>MiR-451a expression significantly downregulation in liver cancer tissues compared with that in normal liver tissue. MiR-451a also obviously low-expressed in liver cancer cell, colorectal carcinoma cell and esophageal carcinoma cell lines. Human hepatoblastoma G2 (HepG2) and BEL-7404 cell lines that stably overexpressed miR-451a by transfecting lentivirus constructed successfully. MTT bromide assay and colony formation assay showed that the overexpressed miR-451a inhibit HepG2 cell proliferation viability, but not BEL-7404 cell. Flow cytometry determined that miR-451a regulating proliferation not through inducing apoptosis. Wound scratch assay revealed that miR-451a overexpression suppressed HepG2 cell migration. Furthermore, mex-3 RNA binding family member C was predicted as the target gene by bioinformatic analysis, and rescue experiments confirmed the hypothesis.<\/jats:p>\n          <jats:p>CONCLUSION<\/jats:p>\n          <jats:p>Therefore, miR-451a may be candidate miRNA for understanding molecular mechanisms of liver cancer development and novel target in liver cancer cell.<\/jats:p>","DOI":"10.5306\/wjco.v16.i9.111742","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:59:12Z","timestamp":1758589152000},"source":"Crossref","is-referenced-by-count":0,"title":["MiR-451a targets mex-3 RNA binding family member C to regulate human hepatoblastoma G2 cell growth and metastasis"],"prefix":"10.5306","volume":"16","author":[{"given":"De-Zheng","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Kuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-Jian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang-Yang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-Kai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-Hai","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0186-y"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0749-z"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2014.11.004"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9740475"},{"key":"B5","unstructured":"Geng F, Lu GF, Ji MH, Kong DY, Wang SY, Tian H, Xie ZM, Pan M, Gong NL. MicroRNA-26b-3p\/ANTXR1 signaling modulates proliferation, migration, and apoptosis of glioma. Am J Transl Res 2019; 7568-7578"},{"key":"B6","unstructured":"Huang WT, Liu AG, Cai KT, He RQ, Li Z, Wei QJ, Chen MY, Huang JY, Yan WY, Zhou H, Chen G, Ma J. Exploration and validation of downregulated microRNA-199a-3p, downstream messenger RNA targets and transcriptional regulation in osteosarcoma. Am J Transl Res 2019; 7538-7554"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S156737"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-019-00627-y"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2016.02.059"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/207684"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cells9010141"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_201809_15818"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-018-0202-x"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1159\/000487006"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29384"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1403-x"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4370-1"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132403"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14673"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/1533033819870209"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13526"}],"container-title":["World Journal of Clinical Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/2218-4333\/full\/v16\/i9\/111742.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/2218-4333\/full\/v16\/i9\/111742.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T01:00:29Z","timestamp":1758589229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/2218-4333\/full\/v16\/i9\/111742.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":21,"journal-issue":{"issue":"9"},"alternative-id":["111742"],"URL":"https:\/\/doi.org\/10.5306\/wjco.v16.i9.111742","relation":{},"ISSN":["2218-4333"],"issn-type":[{"value":"2218-4333","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,24]]}}}